Rituxan MS treatment is cell specific.  Instead of attacking T-cells, the B-cells are reduced in the Rituxan, Multiple Sclerosis off-label use of this popular and widely used cancer drug.  It is thought that the B-cells may play a critical role in the relapse rate of the debilitating disease.  So in finding this new use of Rituxan, MS researchers may have also found a new avenue to pursue in fighting MS by discovering a possible new cause of it.  It is known from previous research with non-Hodgkin’s lymphoma that the drug depletes the B-cells.  And since the relapse rate was so significantly reduced in the Rituxan MS trials, the focus has now shifted to finding out just what role these B-cells play.  Until recently, therapies for MS have focused primarily the T-cells, another immune cell that attacks the fatty myelin coating that insulates the nerves.  It may be that B-cells may …